A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Sponsor
Onconova

Protocol Number
Onconova 04-30

To Learn More Call
201-510-0910